HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Vir Biotechnology, maintaining a price target of $110. Analyst Patrick Trucchio remains optimistic about the company's prospects.
August 20, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Vir Biotechnology, maintaining a price target of $110. Analyst Patrick Trucchio remains optimistic about the company's prospects.
The reiteration of a Buy rating and maintenance of a $110 price target by HC Wainwright & Co. suggests continued confidence in Vir Biotechnology's future performance. This positive analyst sentiment is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100